Dr. Gallagher established SR One’s Boston office in 2010 and is focused on building innovative therapeutic and life science companies. He currently represents SR One on the boards of Aileron (NASDAQ: ALRN), CalciMedica, Constellation Pharmaceuticals, Navitor, Nimbus Therapeutics, Princeps and Translate Bio. He previously led the firm’s investments in River Vision (acquired by Horizon), Dicerna (NASDAQ: DRNA) and SpringLeaf Therapeutics.
Dr. Gallagher has nearly 20 years of investing, business development, operational, and R&D experience in both biotechnology and large pharma companies. He joined SR One from Sirtris Pharmaceuticals where he was responsible for corporate development, operations, and post-merger integration following the $720M acquisition of Sirtris by GlaxoSmithKline in 2008.
Prior to Sirtris, Dr. Gallagher was with Alantos Pharmaceuticals where he played key roles in the R&D and business development activities, and led many aspects of the post-merger integration following the $300M acquisition of Alantos by Amgen in 2007. He began his career in R&D at the Japanese pharma Eisai where he was a group leader for multiple programs in the oncology and inflammation/immunology therapeutic areas.
He is an inventor on over twenty-five patents and patent applications, and is the senior author of a number of scientific publications. He currently serves on the Investment Advisory Board for the University of Michigan’s Monroe-Brown Biomedical Seed Fund and the Industry Advisory Boards for NYU Medical School and the National Brain Tumor Society.
Dr. Gallagher received his MS and PhD degrees in Organic Chemistry from The University of Michigan, and a BS in Chemistry from The University of Massachusetts where he was a Shapiro scholar.